再谈聚乙二醇干扰素α在慢性乙型肝炎个体化治疗中的应用  

Individualized treatment with pegylated interferon-α for chronic hepatitis B

作　　者：万谟彬[1] WAN Mobin(Department of Infectious Diseases,Changhai Hospital of Shanghai,Shanghai 200433,Chin)

机构地区：[1]上海长海医院感染科,上海200433

出　　处：《临床肝胆病杂志》2018年第5期930-933,共4页Journal of Clinical Hepatology

摘　　要：抗病毒治疗是慢性乙型肝炎的根本治疗方法,其中聚乙二醇干扰素(PEG-IFN)α是一线治疗药物之一。目前,PEGIFNα个体化治疗方面已经达成多项共识,在临床实践中发挥了重要作用。随着其临床应用不断深入,逐步涌现出了新的临床需求。结合文献以及个人临床实践经验,阐述了PEG-IFNα对慢性乙型肝炎个体化治疗的一些新认识。Antiviral therapy is the basic treatment of chronic hepatitis B,and pegylated interferon-α is one of the first-line treatment drugs.At present,several consensuses have been reached on individualized treatment with pegylated interferon-o,which is playing an important role in clinical practice.New clinical demands appear along with the clinical application of pegylated interferon-α.With reference to relevant literature and personal clinical experience,this article elaborates on some knowledge of individualized treatment with pegylated interferon-α for chronic hepatitis B.

关 键 词：肝炎 乙型 慢性 干扰素Α 治疗 

分 类 号：R512.62[医药卫生—内科学]